Loading…

China Life2628.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Financials›Multi-Line Insurance

China's largest state-owned life insurer, selling life, health and annuity policies through a huge agent and bank network.

Momentum neutral 44
Mkt cap
$134B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$196M
20-day average traded
P/B
0.93×
price to book
ROE
41.3%
delivered
Implied ROE
10.0%
what the price asks
Next earnings
146 days
1 Apr 2027
Close · HKDHK$25.18
1D-1.7%
1W+5.4%
1M-7.6%
3M-12.6%
6M-17.1%
YTD-5.8%
1Y+3.2%
ATR %3.6%
52w lowhigh28.5% off high

What China Life does

China's largest state-owned life insurer, selling life, health and annuity policies through a huge agent and bank network.

Collects premiums on long-term life, health and annuity policies sold mainly through its own agents and through bank counters, then invests the money, so investment returns matter as much as the policies. The state-owned China Life Insurance (Group) controls it. These Hong Kong shares and the Shanghai ones are the same company.

Products and services

  • Individual life and health policies
  • Group insurance
  • Annuities and pension products
  • Asset management

Customers

  • Mass-market and rural Chinese households

Where it sits in the supply chain

  • Insurance
  • Life and health insurance
  • Individual and bancassurance…

What could go right

  • Rising Chinese insurance penetration
  • Equity-market-linked investment income

What could go wrong

  • Falling long-term rates squeeze guarantees
  • Regulatory product-pricing caps

Moat: narrow (scale, distribution, brand). Largest tied-agent and bancassurance network in China plus state backing, though margins are thin.

Headquarters: Beijing, China · Founded: 1949 · Employees: 97,505

Named competitors

China Life at a glance

Size China Life (2628.HK) is a Hong Kong Financials company (Multi-Line Insurance) with a market value of $134B, the 14th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$25.18 on 6 Nov 2026.

Performance Over six months the shares fell 17.1%, against +14.5% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 38.2% over the last twelve months (peer median +10.3%); the operating margin is 49.8% (peer median 20.0%).

Valuation It trades at 0.93× book value against a peer median of 2.15× (3rd cheapest of 21).

Price implies The share price implies a return on equity of about 10.0%; China Life delivers 41.3%, so the price asks less than the business earns today.

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012011 May 202611 Aug 20266 Nov 2026Peer median 1132628.HK 83
Six months, rebased to 100: China Life against the median of its 20 peers (local-currency closes).

China Life financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$671BHK$588BHK$432BHK$408BHK$462B
Revenue growth—+36%+6%-12%—
Net incomeHK$277BHK$167BHK$116BHK$51.0BHK$77.5B
Free cash flown/aHK$704BHK$607BHK$614BHK$594B
Capital expenditureHK$0HK$0HK$0HK$0HK$3.58B
Total debtn/aHK$409BHK$212BHK$293BHK$221B

Quarterly statements and history in the cockpit →

China Life competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-5%0%+5%+10%601628601318PGR2318ZURN1299CSALV2881METAFLGWOSREN13398725601601AIGSLF2628.HK6-month return →1-month return →
Up and to the right = strong over both horizons. China Life is the large dot.

Fundamentals: return on equity against price-to-book

10%20%30%40%10×20×30×601628601318PGR2318ZURN1299CSALVALL2881METAFLGWOSREN13398725601601POWAIGSLF2628.HKReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. China Life is the large dot.

Capital: ROE delivered against the ROE the price implies

10%20%30%40%20%40%601628PGR2318ZURN1299CSALVALL2881METAFLSREN1339601601AIG2628.HKROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. China Life is the large dot.

China Life competitors and peer comparison

Head to head with its named competitors (2628.HK vs 2318.HK vs 2601.HK vs 1336.HK)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
China Life 2628.HK$134B-17%+38%41%0.93×10.0%
Ping An 2318.HK$138B-17%-8%10%0.79×9.7%
China Pacific Insurance (Group) 2601.HK$42.5B-22%+9%14%0.69×8.4%
New China Life Insurance 1336.HK$21.5B-24%+44%42%0.87×10.3%
AIA 1299.HK$104B-10%+13%20%2.53×18.4%

How China Life compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Life against its 20 peers (data as of 6 Nov 2026)
Measure2628.HKPeer medianRank in peer set
1-month return-7.6%+3.4%lowest of 21
6-month return-17.1%+14.5%lowest of 21
Return on equity41.3%16.3%2nd highest of 21
Price / book0.93×2.15×3rd cheapest of 21
Trailing P/E2.6×12.7×cheapest of 21
ROE the price implies10.0%11.8%10th least demanding of 21
ROE delivered41.3%16.6%2nd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
China Life 2628.HKHong Kong$134B-17%+38%41%0.93×10.0%41.3%
China Life Insurance 601628.SSChina$135B-3%+16%12%1.54×13.1%11.9%
Ping An Insurance (Group) Company of China 601318.SSChina$136B-8%+12%14%0.96×7.4%n/a
Progressive PGRUnited States$132B+17%+8%33%3.82×15.8%33.2%
Ping An 2318.HKHong Kong$138B-17%-8%10%0.79×9.7%9.8%
Zurich Insurance ZURN.SWSwitzerland$114B+16%+19%26%3.67×11.2%25.5%
AIA 1299.HKHong Kong$104B-10%+13%20%2.53×18.4%19.6%
Axa CS.PAFrance$103B+13%+11%19%2.24×17.8%19.0%
Allianz ALV.DEGermany$192B+19%+21%21%2.98×16.0%21.1%
Allstate ALLUnited States$64.4B+20%+6%46%2.04×9.9%46.1%
Fubon Financial Hldg 2881.TWTaiwan$62.7B+66%+12%16%1.66×7.4%16.0%
MetLife METUnited States$62.4B+27%+9%13%2.28×16.2%13.2%
Aflac AFLUnited States$62.2B+10%+14%17%2.06×12.5%16.9%
Great-West Lifeco GWO.TOCanada$57.4B+18%+4%16%3.02×15.7%16.0%
Swiss Re SREN.SWSwitzerland$50.6B+27%-12%20%2.27×6.1%20.4%
People's Insurance Co. (Group) of China 1339.HKHong Kong$46.1B-2%+11%18%0.60×5.6%18.1%
Ms&ad Ins Gp Hldgs 8725.TJapan$44.4B+22%+21%17%1.07×6.9%16.6%
China Pacific Insurance (Group) 601601.SSChina$42.6B-14%+4%14%0.93×8.2%14.4%
Power Corporation of Canada POW.TOCanada$40.7B+16%+10%11%2.42×15.9%11.0%
American International AIGUnited States$40.7B+2%+1%8%1.04×7.5%8.2%
Sun Life Financial SLF.TOCanada$40.1B+7%-1%13%2.38×13.7%13.5%

Questions

Who are China Life's main competitors?
Named competitors: Ping An (2318.HK), China Pacific Insurance (2601.HK), New China Life (1336.HK), AIA (1299.HK). The cockpit's measured peer set (industry) also includes China Life Insurance (601628.SS), Ping An Insurance (Group) Company of China (601318.SS), Progressive (PGR), Ping An (2318.HK), Zurich Insurance (ZURN.SW), AIA (1299.HK).
Is China Life expensive compared with its peers?
On price / book it trades at 0.93× against a peer median of 2.15×, 3rd cheapest of 21 in its peer set. The share price implies a return on equity of about 10.0%; China Life delivers 41.3%, so the price asks less than the business earns today.
How has China Life stock performed?
Over six months to 6 Nov 2026 the shares returned -17.1% against +14.5% for the median peer; over one year +3.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.